Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KTTAW | US
0
0%
Healthcare
Biotechnology
30/06/2024
18/03/2026
0.01
0.01
0.01
0.01
Low Market Beta (-0.4 to 0.8)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
0.0%1 month
0.0%3 months
153.8%6 months
576.1%-
-
-
-
-
-
-
-
-16.27M
-
-
-
-
-
-
-63.25
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.00
Range1M
0.00
Range3M
0.02
Rel. volume
2.55
Price X volume
122.80
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | XOMAO | Biotechnology | 25.442 | 0 | 0.20% | 25.57 | 121.93% |
| SABSW | SABSW | Biotechnology | 0.03 | 0 | 0.00% | 0.17 | 11.58% |
| Revolution Medicines Inc. Warrant | RVMDW | Biotechnology | 1.93 | 0 | 8.43% | n/a | 5.40% |
| Rocket Pharmaceuticals Inc. Warrant | RCKTW | Biotechnology | 0.0178 | 0 | -10.55% | n/a | 0.00% |
| JSPRW | JSPRW | Biotechnology | 0.0204 | 0 | 0.00% | n/a | 2.31% |
| ICUCW | ICUCW | Biotechnology | 0.0298 | 0 | n/a | -45.50% | |
| Humacyte Inc | HUMAW | Biotechnology | 0.0963 | 0 | 1.58% | n/a | -63.37% |
| EyeGate Pharmaceuticals Inc | EYEG | Biotechnology | 35.235 | 0 | -0.30% | n/a | |
| CELUW | CELUW | Biotechnology | 0.008 | 0 | -14.89% | n/a | 127.38% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
No data | |||||||
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | - | - | - |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | - | 15.55 | - |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 153.83 | - | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | - | - | - |